Apoptosis of oligodendrocytes and post-translational modifications of myelin basic protein in multiple sclerosis: Possible role for the early stages of multiple sclerosis

European Neurology

Volumn 63, Issue 2, 2010, Pages 65-72

  Artemiadis, Artemios K ^a   Anagnostouli, Maria C ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Apoptosis; Autoimmunity; MBP molecule; Multiple sclerosis; Oligodendrocytes; Post translational modifications

Indexed keywords

MONOSIALOGANGLIOSIDE; MYELIN BASIC PROTEIN;

APOPTOSIS; AUTOIMMUNITY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; WHITE MATTER;

ANIMALS; APOPTOSIS; HUMANS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; OLIGODENDROGLIA; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 73649144250     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000272940     Document Type: Short Survey

References (70)

1. Flachenecker P: Epidemiology of neuroimmunological diseases. J Neurol 2006; 253(Suppl 5):v2-v8.
2. Becher B, Bechmann I, Greter M: Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 2006; 84: 532-543.
3. Lassmann H, Brück W, Lucchinetti CF: The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-218.
4. Filippi M, Rocca MA: MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system. J Neurol 2005; 252(Suppl 5):v16-v24.
5. Filippi M: Linking structural, metabolic and functional changes in multiple sclerosis. Eur J Neurol 2001; 8: 291-297.
6. Barnett MH, Prineas JW: Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-468.
7. Moscarello MA, Wood DD, Ackerley C, Boulias C: Myelin in multiple sclerosis is developmentally immature. J Clin Invest 1994; 94: 146-154.
8. Blank M, Shiloh Y: Programs for cell death: apoptosis is only one way to go. Cell Cycle 2007; 6: 686-695.
9. Cline AM, Radic MZ: Apoptosis, subcellular particles and autoimmunity. Clin Immunol 2004; 112: 175-182.
10. Nicholson DW, Thornberry NA: Caspases: killer proteases. Trends Biochem Sci 1997; 22: 299-306.
11. Liu G, Wuy C, Wu Y, Zhao Y: Phagocytosis of apoptotic cells and immune regulation. Scand J Immunol 2006; 64: 1-9.
12. Roos A, Xu W, Castellano G, Nauta AJ, Garred P, Daha MR, van Kooten C: Mini-review: A pivotal role for innate immunity in the clearance of apoptotic cells. Eur J Immunol 2004; 34: 921-929.
13. Ronchetti A, Rovere P, Iezzi G, Galati G, Heltai S, Protti MP, Garancini MP, Manfredi AA, Rugarli C, Bellone M: Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen presenting cells and cytokines. J Immunol 1999; 163: 130-136.
14. Gay FW: Early cellular events in multiple sclerosis. Intimations of an extrinsic myelinolytic antigen. Clin Neurol Neurosurg 2006; 108: 234-240.
15. Barnett MH, Parratt JD, Cho ES, Prineas JW: Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009; 65: 32-46.
16. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
17. Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, Dijkstra CD, van der Valk P, Bö L: Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008; 63: 16-25.
18. Barnett MH, Prineas JW: Pathological heterogeneity in multiple sclerosis: a reflection of lesion stage? Ann Neurol 2004; 56: 309.
19. Lucchinetti CF, Bruck W, Lassmann H: Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol 2004; 56: 308.
20. Zeis T, Probst A, Steck AJ, Stadelmann C, Brück W, Schaeren-Wiemers N: Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol 2009; 19: 459-466.
21. Rosen A, Casciola-Rosen L: Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ 1999; 6: 6-12.
22. Rodenburg RJ, Raats JM, Pruijn GJ, van Venrooij WJ: Cell death: a trigger of autoimmunity? Bioessays 2000; 22: 627-636.
23. Lu F, Kalman B: Autoreactive IgG to intracellular proteins in sera of MS patients. J Neuroimmunol 1999; 99: 72-81.
24. Spadaro M, Amendolea MA, Mazzucconi MG, Fantozzi R, Di Lello R, Zangari P, Masala G: Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult Scler 1999; 5: 121-125.
25. Williamson RA, Burgoon MP, Owens GP, Ghausi O, Leclerc E, Firme L, Carlson S, Corboy J, Parren PW, Sanna PP, Gilden DH, Burton DR: Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc Natl Acad Sci USA 2001; 98: 1793-1798.
26. Schweppe RE, Haydon CE, Lewis TS, Resing KA, Ahn NG: The characterization of protein post-translational modifications by mass spectrometry. Acc Chem Res 2003; 36: 453-461.
27. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Fares C: Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron 2004; 35: 503-542.
28. Kim JK, Mastronardi FG, Wood DD, Lubman DM, Zand R, Moscarello MA: Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol Cell Proteomics 2003; 2: 453-462.
29. Harauz G, Musse AA: A tale of two citrullines - structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem Res 2007; 32: 137-158.
30. Gyorgy B, Toth E, Tarcsa E, Falus A, Buzas EI: Citrullination: a posttranslational modification in health and disease. Int J Biochem Cell Biol 2006; 38: 1662-1677.
31. Sambandam T, Belousova M, Accaviti-Loper MA, Blanquicett C, Guercello V, Raijmakers R, Nicholas AP: Increased peptidylarginine deiminase type II in hypoxic astrocytes. Biochem Biophys Res Commun 2004; 325: 1324-1329.
32. Liu GY, Liao YF, Chang WH, Liu CC, Hsieh MC, Hsu PC, Tsay GJ, Hung HC: Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells. Apoptosis 2006; 11: 183-196.
33. Wood DD, Bilbao JM, O'Connors P, Moscarello MA: Acute multiple sclerosis (Marburg type) is associated with developmentally immature myelin basic protein. Ann Neurol 1996; 40: 18-24.
34. Boggs JM, Rangaraj G, Koshy KM, Ackerley C, Wood DD, Moscarello MA: Highly deiminating isoform of myelin basic protein from multiple sclerosis brain causes fragmentation of lipid vesicles. J Neurosci Res 1999; 57: 529-535.
35. Moscarello MA, Brady GW, Fein DB, Wood DD, Cruz TF: The role of charge microheterogeneity of basic protein in the formation and maintenance of the multilayered structure of myelin: a possible role in multiple sclerosis. J Neurosci Res 1986; 15: 87-99.
36. Beniac DR, Wood DD, Palaniyar N, Ottensmeyer FP, Moscarello MA, Harauz G: Cryoelectron microscopy of protein-lipid complexes of human myelin basic protein charge isomers differing in degree of citrullination. J Struct Biol 2000; 129: 80-95.
37. Beniac DR, Wood DD, Palaniyar N, Ottensmeyer FP, Moscarello MA, Harauz G: Marburg's variant of multiple sclerosis correlates with a less compact structure of myelin basic protein. Mol Cell Biol Res Commun 1999; 1: 48-51.
38. McLaurin J, Ackerley CA, Moscarello MA: Localization of basic proteins in human myelin. J Neurosci Res 1993; 35: 618-628.
39. D'Souza CA, Moscarello MA: Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope. Neurochem Res 2006; 31: 1045-1054.
40. Cao L, Goodin R, Wood D, Moscarello MA, Whitaker JN: Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry 1999; 38: 6157-6163.
41. Musse AA, Boggs JM, Harauz G: Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc Natl Acad Sci USA 2006; 103: 4422-4427.
42. Pritzker LB, Joshi S, Gowan JJ, Harauz G, Moscarello MA: Deimination of myelin basic protein. 1. Effect of deimination of arginyl residues of myelin basic protein on its structure and susceptibility to digestion by cathepsin D. Biochemistry 2000; 39: 5374-5381.
43. D'Souza CA, Wood DD, She YM, Moscarello MA: Autocatalytic cleavage of myelin basic protein: an alternative to molecular mimicry. Biochemistry 2005; 44: 12905-12913.
44. Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch HM, Probert L, Casaccia-Bonnefil P, Moscarello MA: Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J Neurosci 2006; 26: 11387-11396.
45. Wood DD, Ackerley CA, Brand B, Zhang L, Raijmakers R, Mastronardi FG, Moscarello MA: Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab Invest 2008; 88: 354-364.
46. Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA: Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J Neurosci Res 2007; 85: 2006-2016.
47. Moscarello MA, Mastronardi FG, Wood DD: The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem Res 2007; 32: 251.
48. Pritzker LB, Joshi S, Harauz G, Moscarello MA: Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase. Biochemistry 2000; 39: 5382-5388.
49. Ng B, Yang F, Huston DP, Yan Y, Yang Y, Xiong Z, Peterson LE, Wang H, Yang XF: Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes. J Allergy Clin Immunol 2004; 114: 1463-1470.
50. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL: Post-translational modifications of naturally processed MHCbinding epitopes. Curr Opin Immunol 2006; 18: 92-97.
51. Zhou Z, Menard HA: Autoantigenic posttranslational modifications of proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol 2002; 14: 250-253.
52. Tranquill LR, Cao L, Ling NC, Kalbacher H, Martin RM, Whitaker JN: Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult Scler 2000; 6: 220-225.
53. Deraos G, Chatzantoni K, Matsoukas MT, Tselios T, Deraos S, Katsara M, Papathanasopoulos P, Vynios D, Apostolopoulos V, Mouzaki A, Matsoukas J: Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP(87-99)) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. J Med Chem 2008; 51: 7834-7842.
54. de Seze J, Dubucquoi S, Lefranc D, Virecoulon F, Nuez I, Dutoit V, Vermersch P, Prin L: IgG reactivity against citrullinated myelin basic protein in multiple sclerosis. J Neuroimmunol 2001; 117: 149-155.
55. Musse AA, Harauz G: Molecular 'negativity' may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. Int Rev Neurobiol 2007; 79: 149-172.
56. Gehrmann J, Matsumoto Y, Kreutzberg GW: Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 1995; 20: 269-287.
57. Nicholas AP, Sambandam T, Echols JD, Tourtellotte WW: Increased citrullinated glial fibrillary acidic protein in secondary progressive multiple sclerosis. J Comp Neurol 2004; 473: 128-136.
58. Akiyama K, Sakurai Y, Asou H, Senshu T: Localization of peptidylarginine deiminase type II in a stage-specific immature oligodendrocyte from rat cerebral hemisphere. Neurosci Lett 1999; 274: 53-55.
59. Miller BA, Crum JM, Tovar CA, Ferguson AR, Bresnahan JC, Beattie MS: Developmental stage of oligodendrocytes determines their response to activated microglia in vitro. J Neuroinflammation 2007; 4: 28.
60. Liu A, Stadelmann C, Moscarello M, Bruck W, Sobel A, Mastronardi FG, Casaccia-Bonnefil P: Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders. J Neurosci 2005; 25: 737-747.
61. Wolswijk G: Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 2000; 123: 105-115.
62. Fukuda A, Fukuda H, Swanpalmer J, Hertzman S, Lannering B, Marky I, Björk-Eriksson T, Blomgren K: Age-dependent sensitivity of the developing brain to irradiation is correlated with the number and vulnerability of progenitor cells. J Neurochem 2005; 92: 569-584.
63. Fragoso G, Martínez-Bermúdez AK, Liu HN, Khorchid A, Chemtob S, Mushynski WE, Almazan G: Developmental differences in HO-induced oligodendrocyte cell death: role of glutathione, mitogen-activated protein kinases and caspase 3. J Neurochem 2004; 90: 392-404.
64. Pugliatti M, Riise T, Sotgiu MA, Satta WM, Sotgiu S, Pirastru MI, Rosati G: Evidence of early childhood as the susceptibility period in multiple sclerosis: space-time cluster analysis in a Sardinian population. Am J Epidemiol 2006; 164: 326-333.
65. Mastronardi FG, Moscarello MA: Molecules affecting myelin stability: a novel hypothesis regarding the pathogenesis of multiple sclerosis. J Neurosci Res 2005; 80: 301-308.
66. Lassmann H, Bartsch U, Montag D, Schachner M: Dying-back oligodendrogliopathy: a late sequel of myelin-associated glycoprotein deficiency. Glia 1997; 19: 104-110.
67. Rodriguez M, Scheithauer BW, Forbes G, Kelly PJ: Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993; 68: 627-636.
68. Davies S, Nicholson T, Laura M, Giovannoni G, Altmann DM: Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis. J Neuropathol Exp Neurol 2005; 64: 371-377.
69. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R: Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000; 123: 508-518.
70. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.